LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics. LEXEO Expands Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases.
LEXEO Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006. Phase I/II clinical trial in patients with cardiomyopathy associated with Friedreich’s ataxia expected to initiate in 2021 NEW YORK –...
LEXEO Therapeutics Announces Upcoming Data Presentations at the ASGCT 2021 Virtual Annual Meeting In collaboration with Weill Cornell Medicine's Department of Genetic Medicine, LEXEO Therapeutics, a clinical-stage gene therapy company,...
LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 LEXEO TX announces FDA fast track designation granted to LX1001 for the treatment of APOE4 Associated Alzheimer's Disease.
LEXEO Therapeutics Strengthens Management Team with Key Appointments LEXEO strengthens management team with key appointments to accelerate development of clinical-stage pipeline.
Jul 28LEXEO Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX1004LEXEO Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX1004
Jul 21LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics.LEXEO Expands Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases.
Jun 30LEXEO Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006.Phase I/II clinical trial in patients with cardiomyopathy associated with Friedreich’s ataxia expected to initiate in 2021 NEW YORK –...
Apr 28LEXEO Therapeutics Announces Upcoming Data Presentations at the ASGCT 2021 Virtual Annual MeetingIn collaboration with Weill Cornell Medicine's Department of Genetic Medicine, LEXEO Therapeutics, a clinical-stage gene therapy company,...
Apr 20LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001LEXEO TX announces FDA fast track designation granted to LX1001 for the treatment of APOE4 Associated Alzheimer's Disease.
Apr 6LEXEO Therapeutics Strengthens Management Team with Key AppointmentsLEXEO strengthens management team with key appointments to accelerate development of clinical-stage pipeline.
Mar 1LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data PackageLexeo completes license of all intellectual property rights and pre-clinical data associated with Adverum's Friedreich's ataxia program.
Jan 6LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies LEXEO Therapeutics, a fully integrated gene therapy company, launches with financing from Longitude Capital and Omega Funds.
